| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134523P | 2015-03-17 | 2015-03-17 | |
| PCT/US2016/022981WO2016149562A2 (en) | 2015-03-17 | 2016-03-17 | Modulation of tumor immunity by protein-mediated 02 delivery |
| Publication Number | Publication Date |
|---|---|
| SG11201707583RAtrue SG11201707583RA (en) | 2017-10-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707583RASG11201707583RA (en) | 2015-03-17 | 2016-03-17 | MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED 0<sb>2</sb> DELIVERY |
| SG10201908269SSG10201908269SA (en) | 2015-03-17 | 2016-03-17 | Modulation of tumor immunity by protein-mediated o2 delivery |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201908269SSG10201908269SA (en) | 2015-03-17 | 2016-03-17 | Modulation of tumor immunity by protein-mediated o2 delivery |
| Country | Link |
|---|---|
| US (2) | US20180243364A1 (en) |
| EP (1) | EP3270961A2 (en) |
| JP (2) | JP7049832B2 (en) |
| KR (1) | KR20170132789A (en) |
| CN (1) | CN107580499A (en) |
| AU (1) | AU2016232866B2 (en) |
| CA (1) | CA2979974A1 (en) |
| HK (2) | HK1249416A1 (en) |
| IL (1) | IL254507B (en) |
| MA (1) | MA41788A (en) |
| MX (1) | MX2017011847A (en) |
| RU (1) | RU2731450C2 (en) |
| SG (2) | SG11201707583RA (en) |
| WO (1) | WO2016149562A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014107171A1 (en)* | 2013-01-07 | 2014-07-10 | Omniox, Inc. | Polymeric forms of h-nox proteins |
| IL254507B (en) | 2015-03-17 | 2022-07-01 | Omniox Inc | Regulation of tumor immunogenicity by a protein that mediates the release of o2 |
| WO2018009528A1 (en)* | 2016-07-05 | 2018-01-11 | Tdw Group | Combination cancer immunotherapies with arginine depletion agents |
| EP3836911A1 (en)* | 2018-08-15 | 2021-06-23 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
| CR20210687A (en) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| JP2022552748A (en) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | Treatment of hematological cancers with anti-CD47 and anti-CD20 |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| PT4081305T (en) | 2019-12-24 | 2024-12-04 | Gilead Sciences Inc | Diacylglycerol kinase modulating compounds |
| CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| CN115698009B (en) | 2020-05-01 | 2025-04-08 | 吉利德科学公司 | CD 73-inhibiting 2, 4-dioxopyrimidine compounds |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| WO2022221431A1 (en)* | 2021-04-14 | 2022-10-20 | OncoC4, Inc. | Use of hif-1-alpha inhibitors in cancer immunotherapy |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7654118B2 (en) | 2021-06-23 | 2025-03-31 | ギリアード サイエンシーズ， インコーポレイテッド | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (en) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Diacylglycerol kinase modulating compounds |
| TWI857377B (en) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| JP2024546851A (en) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| PE20242225A1 (en) | 2022-03-17 | 2024-11-19 | Gilead Sciences Inc | IKAROS FAMILY ZINC FINGER DEGRADERS AND THEIR USES |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (en) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Kras g12d modulating compounds |
| EP4531847A2 (en)* | 2022-05-31 | 2025-04-09 | Cardiff Oncology, Inc. | Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors |
| EP4547657A1 (en) | 2022-07-01 | 2025-05-07 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (en) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | PRMT5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5248766A (en) | 1990-08-17 | 1993-09-28 | Baxter International Inc. | Oxirane-modified hemoglobin based composition |
| US5776898A (en) | 1991-05-14 | 1998-07-07 | Dana-Farber Cancer Institute | Method for treating a tumor with a chemotherapeutic agent |
| US5295944A (en)* | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| WO1992020369A1 (en) | 1991-05-14 | 1992-11-26 | Dana Farber Cancer Institute | Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents |
| US6054427A (en) | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| US5981710A (en) | 1997-07-21 | 1999-11-09 | Baxter International, Inc. | Therapeutic hemoglobin composition having isotropically increased size |
| US20020142957A1 (en)* | 2000-08-07 | 2002-10-03 | Hepler William T. | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20050176108A1 (en)* | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| EP1850852A4 (en) | 2005-02-22 | 2009-11-18 | Cedars Sinai Medical Center | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF AN ABNORMAL BLOOD / BRAIN BARRIER |
| LT1981519T (en) | 2005-12-29 | 2018-04-25 | Dyax Corp. | Protease inhibition |
| EP2027151A2 (en) | 2006-05-15 | 2009-02-25 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| CN101495506B (en) | 2006-05-22 | 2016-08-10 | 加利福尼亚大学董事会 | Compositions and methods for oxygen delivery |
| EP2064235A1 (en) | 2006-09-19 | 2009-06-03 | DKFZ Deutsches Krebsforschungszentrum | The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
| JP2010513405A (en) | 2006-12-21 | 2010-04-30 | ノボ・ノルデイスク・エー／エス | Dimeric prolactin receptor ligand |
| US20110288023A1 (en)* | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| US20100183545A1 (en)* | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| JP2011168521A (en) | 2010-02-18 | 2011-09-01 | Eci Inc | PEGYLATED eMIP, METHOD FOR PRODUCING THE SAME AND CANCER THERAPEUTIC AGENT USING THE SAME |
| US20110243849A1 (en) | 2010-04-02 | 2011-10-06 | Marletta Michael A | Heme-binding photoactive polypeptides and methods of use thereof |
| US8742073B2 (en) | 2010-05-27 | 2014-06-03 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| ES2718308T3 (en) | 2011-01-07 | 2019-07-01 | Poseida Therapeutics Inc | Compositions and methods for administration to tumors of high oxygen affinity binding agents |
| US20140363496A1 (en) | 2011-01-07 | 2014-12-11 | Vindico NanoBio Technology Inc. | Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors |
| WO2016022805A1 (en) | 2014-08-08 | 2016-02-11 | Vindico NanoBio Technology Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| WO2014107171A1 (en) | 2013-01-07 | 2014-07-10 | Omniox, Inc. | Polymeric forms of h-nox proteins |
| WO2014182761A1 (en)* | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
| WO2014193898A1 (en)* | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| JOP20200094A1 (en)* | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody Molecules of PD-1 and Their Uses |
| US20170360706A1 (en) | 2014-12-05 | 2017-12-21 | Vindico Nanobiotechnology, Llc | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
| IL254507B (en) | 2015-03-17 | 2022-07-01 | Omniox Inc | Regulation of tumor immunogenicity by a protein that mediates the release of o2 |
| Publication number | Publication date |
|---|---|
| CA2979974A1 (en) | 2016-09-22 |
| WO2016149562A3 (en) | 2016-11-03 |
| RU2017134953A (en) | 2019-04-08 |
| JP7049832B2 (en) | 2022-04-07 |
| AU2016232866A1 (en) | 2017-10-12 |
| SG10201908269SA (en) | 2019-10-30 |
| WO2016149562A2 (en) | 2016-09-22 |
| IL254507A0 (en) | 2017-11-30 |
| RU2731450C2 (en) | 2020-09-03 |
| US12285463B2 (en) | 2025-04-29 |
| US20220160823A1 (en) | 2022-05-26 |
| MA41788A (en) | 2021-03-31 |
| EP3270961A2 (en) | 2018-01-24 |
| US20180243364A1 (en) | 2018-08-30 |
| BR112017019862A2 (en) | 2018-05-29 |
| HK1250137A1 (en) | 2018-11-30 |
| CN107580499A (en) | 2018-01-12 |
| RU2017134953A3 (en) | 2019-12-26 |
| MX2017011847A (en) | 2018-06-06 |
| JP2020183450A (en) | 2020-11-12 |
| KR20170132789A (en) | 2017-12-04 |
| JP2018511595A (en) | 2018-04-26 |
| HK1249416A1 (en) | 2018-11-02 |
| AU2016232866B2 (en) | 2021-10-21 |
| IL254507B (en) | 2022-07-01 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201707583RA (en) | MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED 0<sb>2</sb> DELIVERY | |
| GB201402257D0 (en) | Novel Peracid - containing particle | |
| PL3265271T3 (en) | Particle feeder | |
| IL251976A0 (en) | טיפול פאג'י | |
| GB201501583D0 (en) | Uses of co-crystals | |
| IL250022A0 (en) | Novel substituted pyrimidine compounds | |
| GB201415783D0 (en) | Particle characterisation | |
| SG11201604954YA (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| EP3191092A4 (en) | Targeting k-ras-mediated signaling pathways and malignancy by prostratin | |
| ZA201606598B (en) | Novel fused imidazobenzothiazole compounds | |
| EP3344280A4 (en) | Formation of bone | |
| GB201600630D0 (en) | Powder formation | |
| EP3162374A4 (en) | Bone formation promoter | |
| TWD174529S (en) | Surface-treating appliances | |
| HUE057240T2 (en) | Cocrystal | |
| IL273520A (en) | Novel salts | |
| EP3170829A4 (en) | Novel salt of tenofovir disoproxil | |
| GB2532702B (en) | The determination of the characteristics of magnets | |
| HK40098901A (en) | Bone formation promoter | |
| GB201401325D0 (en) | Bernard's theory of nutrition | |
| GB201401321D0 (en) | Bernard's theory of domestic goods | |
| GB201401315D0 (en) | Bernard's theory of matter | |
| AU2015903565A0 (en) | Formation of bone | |
| GB201401447D0 (en) | Novel bioactive compounds | |
| GB201401301D0 (en) | Bernard's theory of design |